HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells

Area of Science:

• Cardiovascular Research
• Molecular Biology
• Immunology

Background:

• HMG-CoA reductase inhibitors (statins) are primarily known for lowering cholesterol.
• Emerging evidence suggests statins possess additional mechanisms for reducing coronary heart disease (CHD).
• Monocyte adhesion to endothelium is a critical early event in the development of atherosclerosis.

Purpose of the Study:

• To investigate the effect of statins on monocyte cell adhesion to endothelial cells.
• To determine if statins have anti-atherogenic properties independent of their lipid-lowering effects.

Main Methods:

• Monocytic cell lines (U937, THP-1) and primary human monocytes were pretreated with atorvastatin, cerivastatin, or simvastatin.
• Monocyte adhesion to endothelial cells and vascular cell adhesion molecule-1 (VCAM-1) was measured.
• The effect of statin pretreatment on endothelial cells was also assessed.
• Nuclear factor-kappaB (NF-kappaB) activation was evaluated using cerivastatin.

Main Results:

• Statins significantly reduced monocyte adhesion to endothelium across tested concentrations (0.01-10 microM).
• Pretreatment of endothelium with statins did not alter monocyte adhesion.
• Statin treatment reduced monocyte adhesion to VCAM-1 coated surfaces.
• Cerivastatin inhibited PMA-induced NF-kappaB activation.

Conclusions:

• HMG-CoA reductase inhibitors demonstrate a class effect in reducing monocyte adhesion to endothelium.
• This anti-adhesion mechanism offers a potential additional benefit of statins in preventing coronary heart disease, beyond LDL cholesterol reduction.
• Statins may exert salutary effects in atherogenesis by inhibiting early inflammatory processes like monocyte recruitment.